Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial
- PMID: 9593172
- PMCID: PMC105811
- DOI: 10.1128/AAC.42.5.1293
Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial
Abstract
The prophylactic efficacy of WR 238605, a primaquine analog, was studied with a human Plasmodium falciparum challenge model. A single oral dose of 600 mg, administered 1 day prior to challenge, successfully protected three of four subjects. The fourth subject developed mild, oligosymptomatic malaria on day 31, with drug concentrations one-half of those in the protected individuals. WR 238605 appears to be a promising prophylactic drug for P. falciparum malaria.
Figures
References
-
- Andersen S L, Berman J, Kuschner R, Wesche D, Magill A, Wellde B, Schneider I, Dunne M, Schuster B G. Prophylaxis of Plasmodium falciparum malaria with azithromycin administered to volunteers. Ann Intern Med. 1995;123:771–773. - PubMed
-
- Brueckner, R. P. Unpublished data.
-
- Brueckner, R. P., K. C. Lasseter, E. T. Lin, and B. G. Schuster. First-time-in-human safety and pharmacokinetics of WR 238605, a new antimalarial. Am. J. Trop. Med. Hyg., in press. - PubMed
-
- Brueckner R P, Fleckenstein L. Simultaneous modeling of the pharmacokinetics and methemoglobin pharmacodynamics of an 8-aminoquinoline candidate antimalarial (WR 238605) Pharm Res. 1991;8:1505–1510. - PubMed
-
- Fryauff D J, Baird J K, Basri H, Sumawinata I, Purnomo, Richie T L, Ohrt C K, Mouzin E, Curche C J, Richards A L, Subianto B, Sandjaja B, Wignall F S, Hoffman S L. Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet. 1995;346:1190–1193. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
